There has been a lot happening in the proposed deal between Sanofi-Aventis and Genzyme and in the latest turn of events, Sanofi, the French drug company has said that it will be extending its tender to Genzyme. This would be done, it said, despite presence of 'significant' differences between the two parties.

Sanofi has also reiterated that the offer is not going to see an increase in bidding price. At present, the tender offer stands at $69 per share to which the board of director of Genzyme has already given its negative response. As per the Boston Global this bidding price is just done so that there is some pressure built on board of Genzyme.

Most important and pivotal point of discussions between the two companies is the value of the drug called Lemtrada. This drug is being developed by Genzyme.

Sanofi in its statement has said that there are significant differences in the potential of the drug and that is why they are not able to decide on any one thing.

On Friday, share price of Genzyme was at $71.58 per share at the Nasdaq exchange.